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Abstract 
 
Background and Objective  The aim of this work was to investigate radiomic analysis of 
contrast and non-contrast enhanced planning CT images of oesophageal cancer (OC) patients 
in terms of stability, dimensionality and contrast agent dependency. The prognostic significance 
of CT-based radiomic features was also evaluated.  
 
Methods Different 2D and 3D radiomic features were extracted from contrast and non-
contrast enhanced CT images of 213 patients from the multi-centre SCOPE1 randomised 
controlled trial (RCT) in OC. Feature stability was evaluated by randomly dividing patients 
into three groups and identifying textures with similar distributions among groups with a 
Kruskal-Wallis analysis. A paired two-sided Wilcoxon signed rank test was used to assess for 
significant differences in the remaining corresponding 2D and 3D stable features. A prognostic 
model was constructed using clinical characteristics and remaining filtered features. The 
discriminative ability of significant variables was tested using Kaplan-Meier analysis.  
 
Results A total of 238 2D and 3D radiomic features were computed from oesophageal CT 
images. More than 75 features were stable if extracted from homogeneous cohort (contrast or 
non-contrast enhanced CT images) and inhomogeneous cohort (contrast and non-contrast 
enhanced CT images). Among the remaining corresponding stable features computed from both 
cohorts, only 4 features did not show a statistically significant difference if obtained in 2D or 
in 3D (p-value < 0.05). A Cox regression model constructed using 5 clinical variables (age, 
sex, tumour, node and metastasis (TNM) stage, WHO performance status and contrast 
administration) and 4 radiomic variables (inverse varianceGLCM, large distance emphasisGLDZM, 
zone distance non uniformity normGLDZM, zone distance varianceGLDZM), identified one radiomic 
feature (zone distance varianceGLDZM) that was significantly associated with overall survival 
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(p-value = 0.032, HR = 1.25, 95% CI = 1.02 - 1.52). A significant difference in overall survival 
between groups was found when considering a threshold of zone distance varianceGLDZM equals 
to 1.70 (X2 = 7.692, df = 1, p-value = 0.006). 
 
Conclusion Zone distance varianceGLDZM was identified as the only stable CT radiomic 
feature statistically correlated with overall survival, independent of dimensionality and 
contrast administration. This feature was able to identify high-risk patients and if validated, 
could be the subject of a future clinical trial aiming to improve clinical decision making and 
personalise OC treatment.   
 
 
Key words:  radiomics, features analysis, CT imaging, esophageal cancer.  
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1. Introduction  1 
Oesophageal cancer (OC) is the eighth most common malignancy worldwide with a 5-year 2 
overall survival rate between 15% and 25% [1]. If patients are deemed to have potentially 3 
curable disease, a combination of chemotherapy, radiotherapy and surgery is used, depending 4 
on their tumour, node and metastasis (TNM) stage, physiological fitness and personal choice[2, 5 
3]. Despite these treatment options, many patients still have a poor prognosis, suggesting that 6 
current treatment efficacy is suboptimal and clinical decision making can be improved to better 7 
select which treatment to use for each patient. 8 
Radiological staging largely informs the likely patient prognosis [4], so techniques that 9 
identify prognostic imaging biomarkers from staging investigations may therefore improve 10 
subsequent clinical treatment decisions. A non-invasive approach could assist the risk-11 
stratification of patients with OC, by identifying groups of patients that may respond to 12 
treatment, or those that are likely to suffer side-effects but with little benefit to prognosis. 13 
Radiomics is a new field that has gained increasing attention in recent years [5]. A large 14 
number of quantitative features can be extracted from medical images, including parameters 15 
not appreciated by simple visual analysis, which could improve the prediction of patient 16 
outcomes [6]. Radiomics have been investigated in OC [7, 8]and could be used to inform future 17 
decision support systems [9].  18 
Several studies have focussed on evaluating sensitivity, repeatability and reproducibility of 19 
radiomics features from different imaging modalities and anatomical regions [10, 11, 12, 13]. 20 
The prognostic and predictive value of CT-based radiomics have previously been evaluated in 21 
OC. In the work of Ganeshan et al. [14], the prognostic value of texture analysis was assessed 22 
in non-contrast enhanced CT images, whereas contrast enhanced CT images were used to 23 
predict response to chemoradiotherapy (CRT) in Hou et al. [15] and Nakajo et al. [16]. 24 
However, common limitations of currently published works are the often small sample sizes 25 
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used to perform radiomic analyses and the lack of stability testing of image features across 26 
heterogenous datasets.  27 
A common example of variation in a radiological dataset is the presence or absence of 28 
intravenous (I.V.) contrast in CT examinations. Ideally, staging CT examinations should be 29 
performed with I.V. contrast to improve detection of the tumour, lymph nodes and metastases, 30 
and to aid treatment planning. However, some patients are unable to have I.V. contrast due to 31 
poor renal function or allergy [17].  Administration of I.V. contrast is often desired in clinical 32 
trials although not a pre-requisite for inclusion. Radiomic features that are stable across contrast 33 
versus non-contrast enhanced CT images and 2-dimensional (2D) versus 3-dimensional (3D) 34 
images would overcome this limitation and increase their application across multiple datasets.  35 
Accordingly, the first aim of this study was to evaluate the stability, dimensionality and 36 
contrast agent dependency of radiomic features extracted from contrasted and non-contrast CT 37 
examinations of patients with OC, acquired during the multi-centre SCOPE1 randomised 38 
controlled trial (RCT). The second aim of the work was to evaluate the prognostic significance 39 
of discovered stable radiomic features as potential future imaging biomarkers in personalised 40 
OC staging. 41 
 42 
2. Materials and methods  43 
2.1.   Population and CT imaging 44 
This study retrospectively included a cohort of 213 patients (with radiotherapy planning CT) 45 
recruited into the SCOPE1 trial [18], a National Cancer Research Institute and Cancer Research 46 
UK funded Phase II/III two arm clinical trial investigating definitive CRT with and without 47 
cetuximab in OC. The SCOPE1 trial (EUDRACT 2006-002241-37; ISRCTN 4771849) was 48 
ethically approved by the Research Ethics Committee for Wales on 17/04/2007. The trial was 49 
performed in accordance with the study protocol and monitored by the trial management group.  50 
All patients recruited to SCOPE1 provided written informed consent prior to randomisation and 51 
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treatment initiation. Patients included in the trial were also informed of the strict confidentiality 52 
of their data and the possible review and use by authorised individuals other than their treating 53 
physician [19]. Detailed baseline characteristics of subjects enrolled in this study are presented 54 
in Table 1. 55 
 56 
Table 1. Baseline characteristics of the clinical cohort. 57 
 58 
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 Frequency (%) 
Median age 73 (range 42-90) 
Gender (M:F) 119 (55.9) : 94 (44.1) 
Histology 
Adenocarcinoma 53 (24.9) 
Squamous cell carcinoma 156 (73.2) 
Undifferentiated carcinoma 4 (1.9) 
Tumour 
location 
Upper third 23 (10.8) 
Middle third 98 (46.0) 
Lower third 92 (43.2) 
Contrast agent 
Yes 138 (64.8) 
No 75 (35.2) 
WHO 
performance 
status 
0 110 (51.6) 
1 103 (48.4) 
Stage group 
I 8 (3.8) 
II 41 (19.2) 
III 129 (60.6) 
IV 35 (16.4) 
Treatment 
Control arm (CRT) 108 (50.7) 
Research arm.                     
(CRT + cetuximab) 105 (49.3) 
Overall survival 
Alive 128 (60.1) 
Dead 85 (39.9) 
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Patients underwent CT scan examination in different hospitals in UK. Oesophageal contrast-89 
enhanced and non-contrast enhanced CT data were obtained using different scanners (Siemens, 90 
GE medical systems, Philips) and the following acquisition parameters: 120 kV; 20-641 mAs; 91 
reconstruction diameter, 361 - 700; matrix, 512 × 512; pixel spacing, 0.71 - 1.37 mm; slice 92 
thickness, 2.5 – 5 mm; time between injection and CT, 35-40s. 93 
On each 2D axial CT image, the gross tumour volume (GTV) was manually outlined 94 
following the SCOPE1 protocol by an expert oncologist. The CERR software package [20] was 95 
used to process and import the CT images and radiotherapy volumes. The cohort was stratified 96 
into groups of patients with contrasted (n = 138) and non-contrasted CT (n = 75). 97 
 98 
2.2.  Radiomic features extraction 99 
Using an in-house developed data analytics software [21], radiomic features were 100 
automatically calculated in compliance with the Image Biomarker Standardisation Initiative 101 
(IBSI) [22], an international collaboration aiming to standardise radiomic information extracted 102 
from medical images in order to perform high-throughput quantitative image analysis. Before 103 
extracting the features, CT images were isotropically resampled to 2 mm resolution in all three 104 
directions using linear interpolation. The list of extracted second-order and high-order texture 105 
features included: grey level co-occurrence matrix (GLCM), grey level run length matrix 106 
(GLRL), grey level size zone matrix (GLSZM), grey level distance zone matrix (GLDZM), 107 
neighbourhood grey tone difference matrix (NGTDM). Second-order and high-order features 108 
were obtained considering one segment layer at a time (2D) or considering the whole tumour 109 
volume (3D). Furthermore, GLCM and GLRLM values were calculated by considering two 110 
types of aggregation methods. Texture features were obtained “without merging” when 111 
considering each 2D directional matrix and averaging over 2D directions and slices, or when 112 
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considering each 3D directional matrix and averaging over the 3D directions. Features were 113 
calculated “with merging” when the radiomic value was calculated from a single matrix after 114 
merging all 2D directional matrices or when considering a single matrix after merging all 3D 115 
directional matrices. The list of radiomic features extracted for each oesophageal tumour is 116 
summarized in Table 2. 117 
 118 
Table 2.  Radiomic features extracted from contrast and non-contrast enhanced CT 119 
images. GLCM, grey level co-occurrence matrix; GLRLM, grey level run length matrix; 120 
GLSZM, grey level size zone matrix; GLDZM, grey level distance zone matrix; NGTDM, 121 
neighbourhood grey tone difference matrix. 122 
Texture type Dimension Summarising features Feature computed 
GLCM 2D/3D with/without merging 100 
GLRLM 2D/3D with/without merging 64 
GLSZM 2D/3D - 32 
GLDZM 2D/3D - 32 
NGTDM 2D/3D - 10 
  123 
2.3.  Radiomic features selection and stability comparison  124 
To investigate the possible impact of contrast agents on texture-based features extracted 125 
from CT images of OC, three different groups of patients were analysed: “mixed group” with 126 
contrast and non-contrast enhanced CT scans (n = 213), “contrast group” cohort with CT images 127 
acquired with I.V. contrast (n = 138) and “non-contrast group” with CT images acquired 128 
without I.V. contrast (n = 75). Each group was used as input in the workflow depicted in Fig 1. 129 
Three sub-groups were created by randomly dividing the clinical cohort of patients using the 130 
function “randi” of Matlab (Matlab 2017b; Mathworks, Natick, MA, USA) that generates 131 
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uniformly distributed random integers in a specified interval. From each sub-group, features 132 
were extracted in 2D, in 3D, with and without merging. Features with similar distributions 133 
among sets were identified as stable using the Kruskal-Wallis test. Features with different 134 
distributions were identified as unstable and excluded from further analysis. The remaining 135 
corresponding 2D and 3D stable features within each group were compared to assess for 136 
significant differences with the paired two-sided Wilcoxon signed rank test. Kruskal-Wallis and 137 
paired two-sided Wilcoxon signed rank test were performed using Matlab. For both tests, a p-138 
value of <0.05 was considered statistically significant.  139 
 140 
Fig 1. Workflow used for selecting stable radiomic features. The workflow was repeated 141 
three times using three different groups (a “mixed group” with contrast and non-contrast 142 
enhanced CT images, a “contrast group” with contrast enhanced CT images and a “non-contrast 143 
group” with non-contrast enhanced CT images) as input data. The input group was divided in 144 
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three sub-groups (n = 71 for the mixed group, n = 46 for the contrast group and n = 25 for the 145 
non-contrast group) and processed to extract the features. Stable features, identified as the ones 146 
with similar distributions among the sub- groups, were further analysed. Feature with different 147 
distributions among sub-group (identified as unstable) were not further investigated. 148 
 149 
For each group, stable features that showed no difference if obtained considering one 150 
segment layer at a time in 2D or the whole tumour layers in 3D were grouped and evaluated 151 
with intraclass correlation coefficient (ICC). Features resembling each other (ICC > 0.90) were 152 
removed.  153 
Remaining radiomic features were further investigated to evaluate their potential prognostic 154 
value. A Cox regression model was constructed using 5 clinical variables (age, sex, TNM stage, 155 
WHO performance status and contrast administration) and stable radiomic features. The Cox 156 
regression was computed with a backward conditional method, which has previously been 157 
recommended [23] and used in published studies [8]. Survival comparison was performed with 158 
the Kaplan-Meier life-table method. In particular, the independent cohort of patients enrolled 159 
in this study was divided into three groups equally populated by using prognostic variables 160 
obtained from the Cox regression model. A log-rank test evaluated significant differences in 161 
overall survival (OS). Differences with a p value of < 0.05 were considered statistically 162 
significant. Survival analysis was performed using SPSS Statistics version 23.0 (IBM, Chicago, 163 
IL, USA). 164 
 165 
3. Results  166 
A total of 238 2D and 3D radiomic features were extracted from the CT images of the 167 
oesophagus. Fig 2 shows both stable and unstable radiomic features extracted from the three 168 
groups. The majority of the features were stable in the three sub- groups. Conversely, unstable 169 
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features were identified with the Kruskal-Wallis test in the mixed group (n = 82), contrast group 170 
(n = 3) and non-contrast group (n = 6), respectively, and excluded from further analysis.  171 
 172 
Fig 2. Stable and unstable radiomic features extracted from the three groups. GLCM, 173 
grey level co-occurrence matrix; GLRLM, grey level run length matrix; GLSZM, grey level 174 
size zone matrix; GLDZM, grey level distance zone matrix; NGTDM, neighbourhood grey tone 175 
difference matrix; *, feature computed with merging. 176 
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 177 
As shown in Fig 3, 2D features proved to be more stable then 3D features on contrast-178 
enhanced and non-contrast enhanced CT images of patients with OC. 179 
 180 
Fig 3. Stability of the radiomic features for the three groups assessed. Features were 181 
divided in 2D or in 3D. 182 
 183 
Table 3 summarizes the results obtained after comparing the corresponding 2D and 3D stable 184 
features with the paired two-sided Wilcoxon signed rank test. Among the 76 remaining 185 
corresponding stable features in the mixed group, only 6 features did not show a statistically 186 
significant difference if obtained in 2D or in 3D. For the contrast group, 15 stable features were 187 
not statistically different if extracted in 2D or 3D. The greatest number of stable features (n = 188 
17) that were independent if computed slice-by-slice or from a volume was found in the non-189 
contrast group. Four independent features (inverse varianceGLCM, large distance emphasisGLDZM, 190 
zone distance non uniformity normGLDZM, zone distance varianceGLDZM) were stable across 191 
dimensionality and contrast administration in the three groups considered. Among them, 192 
inverse varianceGLCM was the only feature that also showed to be independent from the type of 193 
aggregation methods used. Comparison of the inverse varianceGLCM obtained with merging and 194 
without merging showed a high correlation (ICC > 0.98). Due to this result, the two features 195 
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were clustered and inverse varianceGLCM obtained without merging was used as leader of the 196 
set in the following analysis.  197 
 198 
Table 3.  List of stable radiomic features not statistically different if extracted using one 199 
segment layer at a time or considering the whole tumour volume in CT images of the 200 
oesophagus. In bold, common features among three cohorts considered that showed to be stable 201 
and dimensionality and contrast agent independent. GLCM, grey level co-occurrence matrix; 202 
GLRLM, grey level run length matrix; GLSZM, grey level size zone matrix; GLDZM, grey 203 
level distance zone matrix; NGTDM, neighbourhood grey tone difference matrix; *, feature 204 
computed with merging. 205 
Texture 
type  Feature 
Mixed       
group 
Contrast   
group 
Non-contrast 
group 
GLCM 
contrast     yes 
Inverse variance yes yes yes 
Inverse variance* yes yes yes 
GLRL 
High GL run emp   yes yes 
Long run low GL emp  yes yes 
RL non uniformity norm  yes yes 
Run percentage  yes yes 
RL variance  yes yes 
High GL run emp*  yes yes 
Long run low GL emp*  yes yes 
Run percentage*  yes yes 
RL variance*   yes yes 
GLSZM Small zone emphasis   yes yes 
GLDZM 
Small distance emphasis yes  yes 
Large distance emphasis yes yes yes 
Zone distance non uniformity norm yes yes yes 
Zone distance variance yes yes yes 
 206 
The Cox regression model was constructed using 5 clinical variables (age, sex, TNM stage, 207 
WHO performance status and contrast) and 4 radiomic variables (inverse varianceGLCM, large 208 
distance emphasisGLDZM, zone distance non uniformity normGLDZM, zone distance 209 
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varianceGLDZM). At the final step of the prognostic model, two variables were found significantly 210 
associated with overall survival: TNM stage (p-value = 0.017, HR = 1.48, 95% CI = 1.07 - 2.05) 211 
and zone distance varianceGLDZM (p-value = 0.032, HR = 1.25, 95% CI = 1.02 - 1.52). Since 212 
TNM stage is already known as a prognostic marker in oesophageal cancer8, only the prognostic 213 
significance of zone distance varianceGLDZM was explored further.  214 
Zone distance varianceGLDZM was found to be correlated with an increased chance of 215 
mortality and was used as a prognostic score to separate patients into three groups each 216 
populated with 71 subjects. The score ranges used for separating the cohort were the following: 217 
for group 1, labelled as low-risk group, from 0.15 to 0.85, for group 2, labelled as intermediate-218 
risk group, from 0.86 to 1.69 and for group 3, labelled as high-risk group, from 1.70 to 6.2. The 219 
median OS of each low, intermediate and high-risk group was 688 days (95% CI 597.4 – 773.4), 220 
554 days (95% CI 532.9 – 700.9), 436.5 days (95% CI 427 – 580.9), respectively. The log-rank 221 
test determined a significant difference (X2 = 7.767, df = 2, p-value = 0.021) as shown in fig 222 
4A. 223 
The significant difference (X2 = 7.692, df = 1, p-value = 0.006) also persisted when merging 224 
the low and the intermediate groups. Fig 4B shows the risk stratification when dividing the 225 
cohort of patients in two groups by considering a threshold of zone distance varianceGLDZM 226 
equal to 1.70. 227 
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 228 
Fig 4. Kaplan-Meier survival curves of the cohort used in this work. Patients divided in 229 
a) low-risk group (zone distance varianceGLDZM from 0.15 to 0.85), intermediate-risk group 230 
(zone distance varianceGLDZM from 0.86 to 1.69) and high-risk group (zone distance 231 
varianceGLDZM from 1.70 to 6.2) based on the prognostic score and b) group 1 (zone distance 232 
varianceGLDZM < 1.70) and group 2 (zone distance varianceGLDZM => 1.70) considering a 233 
threshold of zone distance varianceGLDZM. There was a significant difference in OS when 234 
dividing in low, intermediate and high-risk group (X2 = 7.37, df = 1, p-value = 0.007) or when 235 
using a threshold of zone distance varianceGLDZM (X2 = 7.692, df = 1, p-value = 0.006). 236 
 237 
 238 
4. Discussion 239 
In this study, we evaluated the potential additional value derived from radiomic features 240 
extracted from contrast and non-contrast enhanced CT images of a RCT in the development of 241 
a new prognostic model in OC. In particular, we investigated: 1) the relationship between CT 242 
textures and the administration of I.V. contrast; 2) stability of CT features analysis when 243 
computed in 2D or from a 3D volume in homogeneous and inhomogeneous OC cohorts; and 3) 244 
the prognostic value of stable CT features in current OC staging systems. To the best of our 245 
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knowledge, this is the first study to develop a prognostic model with stable and dimensionality-246 
independent features using clinical RCT trial data of contrast and non-contrast enhanced CT 247 
images of OC patients. 248 
Our analysis showed a statistical dependency of radiomics features extracted from CT scans 249 
on I.V. contrast medium. As expected, radiomic features are more stable if extracted from 250 
homogeneous cohorts. Furthermore, our study showed that most of the stable features extracted 251 
from CT images acquired after the administration of I.V. contrast are also stable when obtained 252 
from cohort of patients scanned without I.V. contrast. This is in line with the recent work of 253 
Badic et al. [24], in which the link between features extracted from contrast enhanced and non-254 
contrast enhanced CT images of primary colorectal cancer of 61 patients was investigated. 255 
However, a comparison with our findings was not possible because even though a large number 256 
of metrics were computed (first-order, second-order and third-order), no GLDZM-based texture 257 
analysis was performed. 258 
We also further investigated differences when radiomic features are extracted in 2D or in 259 
3D. In line with the work of Shen et al. [25], our results have shown that 2D features performed 260 
slightly better than the corresponding 3D ones in the three cohorts considered. In particular, no 261 
2D features were unstable when CT images were acquired with I.V. contrast and only one was 262 
found unstable in the non-contrast group. In general, the number of unstable 3D features was 263 
slightly higher than the number of unstable 2D features. This could be explained by different 264 
voxel sizes of the CT images acquired in this multi-centre study (axial resolution range: 0.71 - 265 
1.37 mm; slice thickness range: 2.5 – 5 mm). The dependency of radiomic features on CT voxel 266 
size has already been investigated in several studies [26, 27]. However, the production of scans 267 
reconstructed to different voxel resolution is frequent in multi-centre trials and even the 268 
implementation of an image resampling method before radiomic feature extraction may not 269 
warrant the complete removal of voxel size dependency. In fact, Mackin et al. [28] showed that 270 
image resampling alone tends to increase the variability of radiomics features extracted from 271 
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CT images of lung cancer patients. They also suggested that the variability can be reduced with 272 
a harmonization the pixel size based on scan resampling in the time domain and a Butterworth 273 
low-pass filtering in the frequency domain. 274 
In general, 2D features extracted from CT images of OC patients performed slightly better 275 
than 3D ones when evaluated in terms of stability, dimensionality and I.V. contrast dependency. 276 
Although, 3D features might carry more information and allow to perform a whole tumour 277 
analysis [29], they are affected by the slice thickness of the imaging data [30] that is typically 278 
higher than the in-plane resolution [31]. However, based on the results of this study we cannot 279 
recommend 2D over 3D features for clinical research and radiomics studies. Future 280 
investigations should consider including the stable features identified in this work. The list of 281 
stable features is reported in S1 Table 4. 282 
Analysis of dimensionality and contrast-independent stable features with the Cox regression 283 
method identified zone distance varianceGLDZM as the only radiomic feature statistically 284 
correlated with OS. GLDZM evaluates the relation between grey levels and location by 285 
counting the number of groups (or zones) of voxels with a specific discretised grey level value 286 
and the same distance to the edge of the ROI considered. In particular, zone distance 287 
varianceGLDZM estimates the variance in zone counts for the different zone distances which 288 
provides a quantitative characterization of tumour heterogeneity. This is known to correlate 289 
with poor prognosis [32]. In agreement with the model, zone distance varianceGLDZM is 290 
significantly associated with overall survival. Patients with increased zone distance 291 
varianceGLDZM have a higher hazard ratio and a therefore shorter life expectancy. In particular, 292 
we have identified a high-risk group above a threshold 1.7 for zone distance varianceGLDZM. 293 
This result confirms the potential prognostic value of textural features measuring tumour 294 
heterogeneity as already shown by different radiomic studies in esophageal [33], lungs [34], 295 
head and neck cancer [35]. This imaging biomarker needs to be tested in a validation dataset to 296 
prove its prognostic value.  297 
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This study has some limitations. Although the great strength of the study is that the data was 298 
obtained from multiple centres in the context of a randomised control trial, validation of the 299 
model constructed using stable features was not performed. According to the TRIPOD scheme, 300 
this study can be classified as a type 1 study in which the development of a prediction model 301 
and the predictive performance are evaluated using the same data. The dataset used in this work 302 
was not split in training and validation set to power the prognostic model appropriately by 303 
reducing as much as possible the rate of false positives (type-I error) and by improving the 304 
ability to detect a true difference between groups (type-II error) [36]. This ensure a high stability 305 
of the model and its transferability and applicability to a wider oesophageal cancer population 306 
independent to contrast administration. Second, the robustness of the extracted radiomic 307 
features in terms of reproducibility and repeatability in contrast and non-contrast enhanced CT 308 
images of OC patients could not be investigated because of the design of the RCT. Future work 309 
will address these limitations by externally validating the prognostic model and by evaluating 310 
the robustness of radiomic features obtained from CT images in different multi-centre datasets. 311 
 312 
 313 
5. Conclusion 314 
We investigated the stability, dimensionality and contrast agent dependency of radiomic 315 
features extracted from contrasted and non-contrast CT examinations of patients with OC, 316 
acquired during the multi-centre SCOPE1 RCT. Zone distance varianceGLDZM was identified as 317 
the only stable CT radiomic feature statistically correlated with overall survival, independent 318 
of dimensionality and contrast administration. This feature was able to identify high-risk 319 
patients and if validated, could be the subject of a future clinical trial aiming to improve clinical 320 
decision making and personalise OC treatment. 321 
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